Loading
The first ten drugs with a Medicare-negotiated price, in effect from 1 January 2026, included one cancer medicine, ibrutinib (Imbruvica). Its price is set per 30-day supply and rose with inflation from 2027.
United States, under the Inflation Reduction Act's Medicare Drug Price Negotiation Program. CMS's data file of 2 November 2026 lists ten selected drugs for initial price applicability year (IPAY) 2026. Ibrutinib (Imbruvica) is the one cancer medicine among them.
The file gives Imbruvica a single maximum fair price of $9,319.00 per 30-day equivalent supply for 1 January to 31 December 2026, and $9,571.07 from 1 January 2027 after the inflation adjustment recorded on 25 November 2025. The file also gives a per-unit price for each package (NDC).
Showing the molecule this term concerns: Ibrutinib.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/